Novo Nordisk Current Ratio 2010-2022 | NVO

Current and historical current ratio for Novo Nordisk (NVO) from 2010 to 2022. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations. Novo Nordisk current ratio for the three months ending June 30, 2022 was 0.94.
Novo Nordisk Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2022-06-30 $14.73B $15.68B 0.94
2022-03-31 $13.05B $14.42B 0.91
2021-12-31 $13.62B $15.83B 0.86
2021-09-30 $14.47B $14.01B 1.03
2021-06-30 $12.51B $11.80B 1.06
2021-03-31 $9.95B $11.73B 0.85
2020-12-31 $10.08B $10.77B 0.94
2020-09-30 $11.57B $11.14B 1.04
2020-06-30 $10.87B $9.94B 1.09
2020-03-31 $9.33B $9.33B 1.00
2019-12-31 $9.36B $8.84B 1.06
2019-09-30 $9.45B $9.40B 1.01
2019-06-30 $8.84B $8.52B 1.04
2019-03-31 $8.03B $8.33B 0.96
2018-12-31 $9.03B $8.28B 1.09
2018-09-30 $8.45B $7.71B 1.10
2018-06-30 $9.21B $7.87B 1.17
2018-03-31 $8.24B $7.29B 1.13
2017-12-31 $9.13B $7.15B 1.28
2017-09-30 $9.02B $7.13B 1.27
2017-06-30 $8.72B $6.48B 1.35
2017-03-31 $7.98B $7.01B 1.14
2016-12-31 $8.88B $7.05B 1.26
2016-09-30 $7.74B $6.24B 1.24
2016-06-30 $7.99B $6.31B 1.27
2016-03-31 $6.86B $6.08B 1.13
2015-12-31 $8.21B $6.08B 1.35
2015-09-30 $7.68B $5.74B 1.34
2015-06-30 $7.02B $5.72B 1.23
2015-03-31 $6.59B $6.37B 1.04
2014-12-31 $8.25B $6.01B 1.37
2014-09-30 $7.33B $5.35B 1.37
2014-06-30 $6.29B $4.37B 1.44
2014-03-31 $6.34B $4.85B 1.31
2013-12-31 $7.49B $4.31B 1.74
2013-09-30 $7.27B $4.56B 1.59
2013-06-30 $6.40B $4.45B 1.44
2013-03-31 $6.34B $4.54B 1.40
2012-12-31 $6.94B $3.74B 1.86
2012-09-30 $6.87B $4.41B 1.56
2012-06-30 $6.21B $4.12B 1.51
2012-03-31 $6.41B $3.88B 1.65
2011-12-31 $7.40B $3.88B 1.91
2011-09-30 $7.37B $3.87B 1.91
2011-06-30 $7.31B $3.59B 2.04
2011-03-31 $6.51B $3.35B 1.94
2010-12-31 $6.65B $3.29B 2.02
2010-09-30 $5.87B $2.93B 2.00
2010-06-30 $5.78B $3.13B 1.85
2010-03-31 $5.84B $2.89B 2.02
2009-12-31 $6.12B $2.51B 2.44
2009-09-30 $5.95B $2.48B 2.40
2009-06-30 $5.44B $2.28B 2.38
2009-03-31 $5.02B $2.48B 2.03
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $243.269B $22.397B
Bagsv?rd, Denmark-based Novo Nordisk is a global healthcare company and a leader in the worldwide diabetes market. The company is also a key player in hemophilia care, growth hormone therapy, hormone replacement therapy and obesity.Novo Nordisk operates through two segments: Diabetes and obesity care and Biopharmaceuticals. While the Diabetes and obesity care segment covers insulins, glucagon-like peptide 1 (GLP-1), other protein-related products, obesity and oral anti-diabetic drugs, the Biopharmaceuticals segment includes hemophilia, growth hormone therapy and hormone replacement therapy.Novo Nordisk's most well-known drugs include Levemir, NovoRapid, Victoza, Ozempic, NovoMix, NovoSeven, NovoThirteen, Ryzodeg, Xultophy, Saxenda, Rybelsus, Esperoct, Sogroya and Norditropin, among several others. The company launched its first product for weight management, Saxenda, in the United States in 2015.In August 2018, Novo Nordisk announced that it has acquired all of the shares of Ziylo Ltd.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $434.603B 16.55
Eli Lilly (LLY) United States $292.730B 37.12
Pfizer (PFE) United States $281.235B 8.24
AbbVie (ABBV) United States $252.131B 10.71
Merck (MRK) United States $230.579B 12.04
Novartis AG (NVS) Switzerland $189.576B 13.98